NK cell modifications to advance their anti-tumor activities

scroll to explore
Cover image for research topic "NK cell modifications to advance their anti-tumor activities"
ChatGPT summary

Exploring new therapeutic approaches to enhance efficacy of NK cells against tumors

Recent research has revealed a number of promising immunotherapeutic strategies for cancer treatment, including the use of natural killer (NK) cells, chimeric antigen receptors (CARs), and neoantigens presented by major histocompatibility complex (MHC) molecules.

NK cells have been found to play an important role in antitumor immunity, with research creating a prognostic profile based on NK cell marker genes that can accurately predict the effectiveness of immunotherapy for HCC patients. NKT cells, divided into type I and type II, interact with other cells in the liver and are involved in the treatment of various liver diseases. B7-H3 mAb with a variant Fc part has been found to trigger profound NK cell functions and result in potent lysis of different sarcoma cells. NK cells are also being explored as a potential target for immunotherapeutic attempts, with preclinical and clinical strategies for harnessing NK cells for cancer treatment being developed.

In addition, CARs have been used to engineer T lymphocytes to treat blood cancers, and NK cells are now being explored as an alternative candidate for retargeting cancer due to their unique recognition mechanisms and powerful cytotoxic effects. Combining GMP-NK cell immunotherapy with checkpoint inhibitor (CPI) strategies could be an attractive therapeutic option for HCC. Antibodies targeting PD-1/PD-L1 have also been found to be effective in treating a variety of cancers, potentially due to an enhancement of NK-cell function and activity.

The ChatGPT summary is generated out of the summaries of the individual article abstracts.